Polarean Imaging seeks to raise $4.3M in IPO on London Exchange

Dollars
North Carolina devicemaker Polarean plans to raise as much as $4.3 million in a public offering on the London Stock Exchange. (Pixabay)

Polarean, a North Carolina-based devicemaker focused on the MRI market, said it plans to raise as much as $4.3 million (£3 million) in a public offering listing on the AIM Market of the London Stock Exchange.

The company said it expects the IPO launch by the end of this week. Polarean, which will be traded under the symbol POLX, said it plans to use the funds along with money raised from a previous convertible loan note to support clinical trials and eventual FDA approval of its MRI-enhancing technology.

Polarean’s technology would allow current MRI systems to gain improved levels of pulmonary function imaging to aid early diagnosis of pulmonary disease, which currently affects hundreds of millions of people globally. An estimated 174 million people suffer chronic obstructive pulmonary disease (COPD), which is responsible for 6% of all deaths worldwide each year, the company said.

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

“We believe we have established a technology that targets a huge unmet medical need to aid the diagnosis of pulmonary diseases and are well positioned to achieve the key milestones we have set out, including for the execution of our Phase III clinical trial in the U.S.,” Richard Hullihen, Polarean’s chief executive, said in a statement.

Polarean’s Phase III trial for its imaging technology is expected to begin in early second-quarter 2018 and is expected to last for about 18 months as it prepares its NDA to the regulatory agency. 

The company currently manufactures high performance MRI radio frequency coils that are required components for imaging 129Xe in the MRI system.

Read more on

Suggested Articles

What the NASH field needs, says Genfit CEO Pascal Prigent, is something like the Hb1Ac test for diabetes.

Dubbed “Project Nightingale,” the efforts were announced amid concerns and federal inquiries into the data’s safekeeping and patient consent for use.

Exact Sciences received an FDA breakthrough designation for its liver cancer blood test as it finalized its $2.8 billion merger with Genomic Health.